KIT and lung cancer: Our data in clinical isolates are consistent with the findings of Levina et al., who demonstrated imatinib sensitivity of “cancer stem cells” expanded from spheroids derived from the lung cancer cell lines H460 and A549, and demonstrated the presence of an autocrine loop in which KIT + tumor cells secret the kit-ligand Stem Cell factor [45].